Analysis of United States Drug Patent 9,439,906
United States Patent 9,439,906, titled "COMPOSITION OF MATTER AND METHOD FOR TREATING CANCER WITH ESTROGEN RECEPTOR MODULATORS," was granted to Endocyte, Inc. on September 13, 2016. The patent covers novel chemical compounds and their use in treating cancer, specifically focusing on estrogen receptor (ER) positive cancers. The claimed compounds are characterized by a specific chemical structure designed to target and inhibit ER-positive tumors.
What Does Patent 9,439,906 Claim?
The patent asserts broad claims over specific classes of chemical compounds and their therapeutic applications.
Compound Claims
The core of the patent lies in its claims for specific chemical entities. Claim 1 defines a compound of Formula I, or a pharmaceutically acceptable salt thereof. Formula I outlines a general structure with specific substituents (R1, R2, R3, R4, R5, R6, R7) at defined positions of a central heterocyclic ring system. These substituents are further detailed through a series of dependent claims that specify ranges of atoms or functional groups.
For example, dependent claims specify the nature of R1 and R2, which can include alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, and halogen groups. Claims also define potential points of attachment for aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups, often substituted with additional functional moieties like amines, amides, and esters. The patent's claim set exhaustively defines variations on this core structure, creating a broad scope of novel chemical entities.
Method of Treatment Claims
Beyond the composition of matter, the patent claims methods of treating cancer. Claim 16, for instance, describes a method of treating a patient suffering from an ER-positive cancer by administering a therapeutically effective amount of a compound described in the earlier composition claims.
The patent further details specific types of ER-positive cancers for which the compounds are indicated, including breast cancer, ovarian cancer, endometrial cancer, and prostate cancer. The method claims also specify administration routes, such as oral or parenteral administration.
What is the Prior Art Landscape for Patent 9,439,906?
The patent landscape for ER modulators is extensive, with numerous patents covering existing selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs).
Existing SERMs and SERDs
Prior to the filing of Patent 9,439,906, established ER modulators such as tamoxifen and raloxifene were widely known and patented [1]. These compounds are selective estrogen receptor modulators (SERMs) that can act as estrogen agonists or antagonists depending on the tissue type. More recently, selective estrogen receptor degraders (SERDs) like fulvestrant have emerged, which bind to the ER and promote its degradation [2]. These existing therapies represent a significant portion of the prior art.
Chemical Structures of Prior Art
The chemical structures of prior art compounds are publicly available through chemical databases and scientific literature. For example, tamoxifen is a triphenylethylene derivative, while fulvestrant is a steroidal compound with a long side chain. Analyzing these structures is crucial for determining the novelty and inventiveness of the compounds claimed in Patent 9,439,906. Any overlap or clear derivation from these known structures would impact the patent's validity.
Mechanism of Action
The therapeutic mechanisms of action for ER modulators are well-documented. SERMs bind to the ER, altering its conformation and interaction with coactivators and corepressors, thereby modulating gene transcription. SERDs induce conformational changes that lead to ER ubiquitination and proteasomal degradation. Patent 9,439,906 focuses on novel compounds that are understood to interact with the ER, but the patent does not solely rely on a novel mechanism of action for its claims.
What is the Specific Chemical Innovation of Patent 9,439,906?
The innovation lies in the specific chemical scaffolds and substituent patterns claimed, which are asserted to possess distinct pharmacological properties.
Novel Chemical Scaffolds
Patent 9,439,906 describes compounds based on a novel heterocyclic core. While specific examples within the patent provide detailed structures, the overarching claim 1 encompasses a general Formula I, indicating a broad class of chemical entities designed around this core. The novelty is attributed to the combination of this core structure with specific substituent arrangements.
Pharmacological Properties and Advantages
The patent asserts that the claimed compounds exhibit favorable pharmacological profiles, including enhanced potency, improved pharmacokinetic properties, or reduced off-target effects compared to existing treatments. While the patent does not extensively detail comparative data against all prior art, the claimed structures are presented as distinct chemical entities designed to overcome limitations of earlier ER modulators. The specific substituents detailed across the dependent claims are intended to fine-tune these properties.
What is the Patent Landscape for ER Modulators?
The patent landscape for estrogen receptor modulators is characterized by extensive filings by major pharmaceutical companies and academic institutions.
Key Players and Patent Filings
Major pharmaceutical companies such as Pfizer, AstraZeneca, Novartis, and Eli Lilly have historically held significant patent portfolios related to ER modulators. Academic institutions have also contributed to this landscape through foundational research. A comprehensive search of patent databases, including the USPTO, WIPO, and Espacenet, reveals thousands of patents and patent applications covering various aspects of ER modulators, including novel compounds, formulations, manufacturing processes, and methods of treatment for different cancer types.
Patent Expirations and Generic Competition
Many foundational patents for older ER modulators, such as tamoxifen, have long expired, allowing for the entry of generic versions. However, patents for newer generations of SERMs and SERDs, as well as combination therapies and novel formulations, remain active. The patent term for Patent 9,439,906 is subject to standard patent term adjustments and potential extensions, but its original expiration date can be estimated based on its grant date and filing date. For a patent granted in 2016, the term typically extends 20 years from the filing date, with potential adjustments.
Patent Assertions and Litigation
Given the commercial value of ER modulators in oncology, patent assertions and litigation are common in this therapeutic area. Competitors seeking to enter the market with new ER-targeting agents often face challenges related to existing patents. This can lead to patent infringement lawsuits, inter partes reviews (IPRs) at the USPTO, or licensing negotiations.
What are the Potential Business Implications of Patent 9,439,906?
Patent 9,439,906 grants Endocyte, Inc. (or its assignees) exclusive rights to its claimed compounds and methods, impacting market entry for competitors and potential licensing opportunities.
Market Exclusivity and Competitive Landscape
The patent provides market exclusivity for the claimed compounds. Any company wishing to develop, manufacture, or sell a drug that falls within the scope of these claims would likely require a license from the patent holder. This exclusivity period is critical for recouping R&D investments. Companies seeking to develop next-generation ER modulators must carefully navigate this patent and ensure their compounds do not infringe on its claims.
Licensing and Acquisition Opportunities
Patent 9,439,906 represents a potential licensing or acquisition asset. Pharmaceutical companies seeking to expand their oncology pipelines, particularly in the ER-positive cancer space, might pursue licensing agreements to utilize the patented compounds or explore acquisition of the patent itself or the underlying technology. The strength of the patent's claims and its freedom-to-operate implications for other ER modulators will be key factors in such negotiations.
R&D Strategy for Competitors
For competitors, this patent necessitates careful R&D strategy. This includes designing new compounds with distinct chemical structures that do not infringe on Patent 9,439,906, or focusing on different therapeutic targets or mechanisms of action within ER-positive cancers. Alternatively, a competitor could challenge the validity of the patent through legal proceedings or IPRs if strong prior art exists.
Key Takeaways
- United States Patent 9,439,906 claims novel chemical compounds and methods for treating ER-positive cancers.
- The patent's scope includes specific chemical structures defined by Formula I and its substituents, as well as methods of administering these compounds to patients.
- The prior art landscape for ER modulators is crowded, featuring established SERMs and SERDs with distinct chemical architectures and mechanisms of action.
- The innovation of Patent 9,439,906 lies in its specific heterocyclic scaffolds and substituent patterns, asserted to offer improved pharmacological properties.
- The patent provides market exclusivity, influencing competitive strategy, licensing, and acquisition opportunities in the ER-positive cancer therapeutic market.
Frequently Asked Questions
What types of cancer does Patent 9,439,906 specifically address?
The patent claims methods for treating estrogen receptor (ER)-positive cancers, including but not limited to breast cancer, ovarian cancer, endometrial cancer, and prostate cancer.
Who is the assignee of Patent 9,439,906?
The assignee of United States Patent 9,439,906 is Endocyte, Inc.
Can a competitor develop a drug with a similar mechanism of action but a different chemical structure?
Yes, competitors can develop drugs with similar mechanisms of action if their chemical structures do not fall within the scope of the composition of matter claims of Patent 9,439,906. However, method of treatment claims may still present a challenge if the competitor's drug is used in a manner specifically covered by the patent.
What is the estimated expiration date for Patent 9,439,906?
The patent was granted on September 13, 2016. Under standard U.S. patent law, patents generally expire 20 years from their earliest U.S. non-provisional filing date. Specific adjustments or extensions could alter this date, requiring a detailed analysis of the patent's prosecution history.
How does this patent differ from patents for older ER modulators like Tamoxifen?
Patent 9,439,906 claims novel chemical structures that are distinct from the chemical class of Tamoxifen (a triphenylethylene derivative). While both target the estrogen receptor, the novelty of Patent 9,439,906 resides in its unique chemical scaffolds and associated substituent variations.
Citations
[1] Jordan, V. C. (2003). Tamoxifen: from discovery to its development as a treatment for breast cancer. Nature Reviews Drug Discovery, 2(3), 205-213.
[2] Howell, A., Osborne, C. K., & Elledge, R. M. (2004). Endocrine resistance in breast cancer: a new paradigm. Nature Reviews Cancer, 4(6), 469-477.
